EGFR Testing for Metastatic Non-Small Cell Lung Cancer with Jonathan W. Riess, MD, MS: Case 4 : Episode 1
CASE 4: 52-Year-Old Man with Relapsed Metastatic NSCLC
Jonathan W. Riess, MD, MS:
Riess case 4:
52-year-old man with relapsed metastatic NSCLC.
- 52-year-old man developed NSCLC, metastatic to the bone and brain
- Was found to have an EGFR activating mutation
- Started on erlotinib with a good response, received radiotherapy to hip and brain
- After 12 months he developed cough and dyspnea on exertion
- CT scan showed progression in the primary lesion and multiple other pulmonary nodules
- Tissue biopsy showed an EGFR T790M mutation
- Subsequent treatment with osimertinib resulted in tumor shrinkage as well as resolution of his symptoms.
Related Videos
Related Content
FDA Grants Breakthrough Therapy Designation to Sunvozertinib in EGFR Exon20+ NSCLC
April 9th 2024Article
Sunvozertinib was granted breakthrough therapy designation by the FDA for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer harboring an EGFR exon 20 insertion mutation.
Read More
